ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)

ClinicalTrials.gov ID: NCT02727699

Public ClinicalTrials.gov record NCT02727699. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Study identification

NCT ID
NCT02727699
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Actinogen Medical
Industry
Enrollment
185 participants

Conditions and interventions

Interventions

  • Placebo (for Xanamem™) Drug
  • Xanamem™ Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 22, 2017
Primary completion
Mar 14, 2019
Completion
Mar 14, 2019
Last update posted
Feb 2, 2025

2017 – 2019

United States locations

U.S. sites
14
U.S. states
8
U.S. cities
14
Facility City State ZIP Site status
Tucson Neuroscience Research, LLC Tucson Arizona 85710
National Research Institute Los Angeles California 90057
PCND Neuroscience Research Institute Poway California 92064
Pacific Research Network, Inc. San Diego California 92103
Research Alliance Inc. Clearwater Florida 33756
The Neurology Research Group, LLC Miami Florida 33186
Compass Research LLC Orlando Florida 32806
IMIC, Inc. Palmetto Bay Florida 33157
Atlanta Center for Medical Research Atlanta Georgia 30331
NeuroStudies.Net, LLC Decatur Georgia 30033
The NeuroCognitive Institute Mount Arlington New Jersey 07856
Richmond Behavioral Associates Staten Island New York 10312
PMG Research of Rocky Mount, LLC Rocky Mount North Carolina 27804
The Clinical Trial Center Jenkintown Pennsylvania 19046

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02727699, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02727699 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →